Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca\textsuperscript{2+} channel

Hironao Saegusa, Takashi Kurihara, Shuqin Zong, An-a Kazuno, Yoshihiro Matsuda, Takahiro Nonaka, Wenhua Han, Hideyuki Toriyama and Tsutomu Tanabe

Department of Pharmacology and Neurobiology, Graduate School of Medicine, Tokyo Medical and Dental University and CREST, Japan Science and Technology Corporation, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan

1Corresponding author

e-mail: t-tanabe.mphm@tmtd.ac.jp

H.Saegusa and T.Kurihara contributed equally to this work

The importance of voltage-dependent Ca\textsuperscript{2+} channels (VDCCs) in pain transmission has been noticed gradually, as several VDCC blockers have been shown to be effective in inhibiting this process. In particular, the N-type VDCC has attracted attention, because inhibitors of this channel are effective in various aspects of pain-related phenomena. To understand the genuine contribution of the N-type VDCC to the pain transmission system, we generated mice deficient in this channel by gene targeting. We report here that mice lacking N-type VDCCs show suppressed responses to a painful stimulus that induces inflammation and show markedly reduced symptoms of neuropathic pain, which is caused by nerve injury and is known to be difficult to treat by currently available therapeutic methods. This finding clearly demonstrates that the N-type VDCC is essential for development of neuropathic pain and, therefore, controlling the activity of this channel can be of great importance for the management of neuropathic pain.

Keywords: Ca\textsubscript{2,2}/gene targeting/N-type calcium channel/pain

Introduction

The voltage-dependent Ca\textsuperscript{2+} channel (VDCC) is a molecular complex containing several subunits named \(\alpha_1\), \(\alpha_2-\delta\), \(\beta\) and \(\gamma\) (Catterall, 1998; Hofmann et al., 1999). The \(\alpha_1\)-subunit is essential for channel functions and determines fundamental channel properties. VDCCs are classified into several groups (L-, N-, P-, Q-, R- and T-types) based on electrophysiological and pharmacological properties. On the other hand, molecular biological studies have identified 10 different cDNAs each coding for an \(\alpha_1\)-subunit in various tissues of mammalian species and they are divided into three groups (Ca\textsubscript{1}, Ca\textsubscript{2} and Ca\textsubscript{3} families) according to their sequence similarities (Ertel et al., 2000). The Ca\textsubscript{1} family (Ca\textsubscript{1,1}, 1.2, 1.3 and 1.4, also referred to as \(\alpha_{1S}\), \(\alpha_{1C}\), \(\alpha_{1D}\) and \(\alpha_{1E}\), respectively) corresponds to dihydropyridine-sensitive L-type channels, and the Ca\textsubscript{3} family (Ca\textsubscript{3,1}, 3.2 and 3.3, also referred to as \(\alpha_{1G}\), \(\alpha_{1H}\) and \(\alpha_{1I}\), respectively) corresponds to low-voltage activated T-type channels. Neuronal high-voltage activated channels resistant to dihydropyridines contain an \(\alpha_1\)-subunit belonging to the Ca\textsubscript{2} family, which includes Ca\textsubscript{2,1}, Ca\textsubscript{2,2} and Ca\textsubscript{2,3} (also referred to as \(\alpha_{1A}\), \(\alpha_{1B}\) and \(\alpha_{1E}\), respectively). Ca\textsubscript{2,1} is thought to support the P- and Q-type Ca\textsuperscript{2+} currents and to play critical roles in neurotransmitter release at central synapses. Ca\textsubscript{2,3} is thought to contribute to the R-type channel first identified in cerebellar granule cells (Zhang et al., 1993; Piedra-Renteria and Tsien, 1998; Tottene et al., 2000), though controversy still exists as to whether this subunit also constitutes the T-type channel. With regard to Ca\textsubscript{2,2}, protein purification studies have shown that this subunit is a component of the N-type channel (Witcher et al., 1993), which, like P/Q-type channels, plays critical roles in the regulation of neurotransmitter release (Catterall, 1998).

Recently, mice with a targeted mutation in each of the Ca\textsubscript{2,1} and Ca\textsubscript{2,3} channels have been reported. Ca\textsubscript{2,1}-null mice showed progressive ataxia and absence epilepsy, and the important roles of Ca\textsubscript{2,1} channels in synaptic transmission were demonstrated (Jun et al., 1999). Ca\textsubscript{2,3}-null mice showed increased anxiety and abnormal nociceptive and antinociceptive behaviors, suggesting multiple roles for the Ca\textsubscript{2,3} channel in the nervous system (Saegusa et al., 2000). Thus, studies with mice carrying a null mutation for the Ca\textsuperscript{2+} channel can provide valuable information on the physiological functions of the channel, and therefore mice mutant for the Ca\textsubscript{2,2} channel have been awaited to complete the genetic analyses of the functions of the Ca\textsubscript{2} family.

Recent studies have suggested that VDCCs are involved in pain transmission (Vanegas and Schaible, 2000). In particular, the N-type VDCC is thought to be important for various aspects of pain-related phenomena and, from a therapeutic point of view, its blockers such as \(\alpha\)-conopeptides have attracted attention as antinociceptives (Chaplan et al., 1994b; Malmberg and Yaksh, 1994; Bowersox et al., 1996; Neugebauer et al., 1996; Diaz and Dickinson, 1997; Sluka, 1998). It is therefore important to elucidate the contribution of the N-type VDCC to development of pain symptoms in order to understand the molecular mechanisms of pain transmission and establish novel therapeutic means.

In the present study, we have established a mouse line lacking the N-type VDCC by gene targeting and found that the mutant mice exhibited various abnormal pain-related behaviors. In particular, the homozygous mutant mice developed a markedly reduced level of neuropathic pain, which is caused by nerve injury and for which no conventional remedies have been successful (Devor and Seltzer, 1999; Woolf and Mannion, 1999). Thus, the
N-type VDCC mutant mice would provide an excellent opportunity to delineate the signal transduction mechanisms leading to neuropathic pain.

**Results**

**Generation of Ca$_{v}$.2.2 mutant mice**

We constructed a replacement-type targeting vector, BIIIZneoII, and introduced linearized BIIIZneoII into J1 embryonic stem (ES) cells by electroporation (Figure 1A). After screening 134 G418-resistant clones, one targeted clone, which yielded germline chimeric mice, was obtained. Germline transmission of the targeted allele was confirmed by Southern blot analysis (Figure 1B). Heterozygous mutant (Ca$_{v}$.2.2+/−) mice were intercrossed to obtain homozygous mutant (Ca$_{v}$.2.2−/−) mice; however, −30% of the Ca$_{v}$.2.2−/− mice were lost before weaning (+/+; +/+; +/+; +/+; +/+; +/+; +/+ = 49:97:36 at weaning). At present, the reason for the premature death of Ca$_{v}$.2.2−/− mice is not clear. Heterozygous mutant mice that survived thereafter look normal without showing any apparent motor dysfunction.

To confirm the gene disruption, we have performed RT–PCR, northern blot and immunoblot analyses. All of the results indicate that the Cacna1b gene encoding the α2.2 subunit (for nomenclature see Ertel et al., 2000) is disrupted as expected (Figure 1C–E). Thus, we conclude that a null allele for Cacna1b was successfully produced by our targeting strategy.

To examine whether the disruption of the Cacna1b gene resulted in the complete loss of the N-type Ca$^{2+}$ current, we performed electrophysiological studies. By whole-cell patch-clamp recording, Ca$^{2+}$ currents from acutely dissociated small dorsal root ganglion (DRG) neurons were examined in both wild-type (Ca$_{v}$.2.2+/+) and Ca$_{v}$.2.2−/− mice. In our experimental conditions, Ba$^{2+}$ was used as a charge carrier. First, we characterized the voltage dependence of current activation. Figure 2A shows typical superimposed current traces and averaged current−voltage (I−V) relationships in Ca$_{v}$.2.2+/+ and Ca$_{v}$.2.2−/− neurons. The I−V relationships were similar in both genotypes, though the I−V curve in Ca$_{v}$.2.2−/− mice shifted slightly toward the hyperpolarizing direction.

Next we examined the effects of sequential application of VDCC blockers on the peak current evoked by voltage steps to −10 mV delivered at 10–20 s intervals. In our experiments, the DRG neurons were separated into two groups according to the cell capacitance (those <15 pF and those within the range of 18.2–38 pF). The sensitivities to toxins were essentially the same between these two groups, consistent with the previous data for rat DRG neurons (Scroggs and Fox, 1992). We therefore combined data from both groups of DRG neurons. In Figure 2B, representative time course data from Ca$_{v}$.2.2+/+ and Ca$_{v}$.2.2−/− DRG neurons are shown. In the Ca$_{v}$.2.2+/+ neuron, bath application of 1 μM ω-conotoxin GVIA, an N-type channel blocker, clearly inhibited the peak Ba$^{2+}$ current, and subsequent application of 0.2 μM ω-agatoxin IVA, a P/Q-type channel blocker, further blocked the Ba$^{2+}$ current (Figure 2B, top). On average, ω-conotoxin GVIA blocked 30.0 ± 6.80% (n = 7) of the peak current, and subsequent application of ω-agatoxin IVA blocked 28.8 ± 2.65% (n = 5) of the original peak current in Ca$_{v}$.2.2+/+ DRG neurons. In contrast, the same dosage of ω-conotoxin GVIA was almost completely ineffective and the effect was indistinguishable from the current run-down in Ca$_{v}$.2.2−/− DRG neurons (Figure 2B, bottom). However, subsequent application of ω-agatoxin VIA blocked the Ba$^{2+}$ current. On average, in Ca$_{v}$.2.2−/− DRG neurons, ω-conotoxin GVIA blocked −1.54 ± 2.65% (n = 8), and subsequent application of ω-agatoxin IVA blocked 35.8 ± 7.98% of the peak Ba$^{2+}$ current (n = 8; not significantly different from the value obtained for Ca$_{v}$.2.2+/+ DRG neurons), suggesting no compensatory up-regulation of P/Q-type channels in these small DRG neurons. Thus, the ω-conotoxin-sensitive N-type current is thought to be derived solely from the Ca$_{v}$.2.2 channel.

**Abnormal anxiety-related behaviors of Ca$_{v}$.2.2 mutant mice**

Although the general behaviors of the Ca$_{v}$.2.2−/− mice, which survived to adulthood, looked normal, we
performed several behavioral tests to search for possible abnormalities. Each mouse was subjected to elevated plus-maze, open-field and startle response tests in this order, with an ~1 week interval between each test. In the elevated plus-maze test, we recorded the number of entries into each of the open and closed arms and time spent in each of the arms, by which the level of anxiety of the animal was assessed. Usually mice do not like to be exposed in the open arm, and Ca_{2.2}+/+ mice actually tended to enter the closed arms preferentially and spent more time in the closed arms. However, on the contrary, Ca_{2.2}−/− mice entered the open arms significantly more frequently and the total time spent in the open arms in the Ca_{2.2}−/− mice tended to be longer (Figure 3A and B). These results suggest the lowered level of anxiety in Ca_{2.2}−/− mice.

We then examined the spontaneous locomotor activity and anxiety to a novel environment of the Ca_{2.2} mutant mice by the open-field test. The total time of movement and the total distance traveled were calculated during 2.5 min of free activity. It is thought that less activity is a sign of anxiety. The total time of behavior was not significantly different among the three genotypes (Figure 3C). However, the total distance traveled by Ca_{2.2}−/− mice was significantly longer (Figure 3D). This could also be a manifestation of reduced anxiety in Ca_{2.2}−/− mice.

Finally, we examined the acoustic startle responses of the Ca_{2.2}−/− mice. Mice received acoustic stimuli of 105, 115 and 120 dB in a randomized order and the startle response to each sound stimulus was recorded with an accelerometer to monitor their movement. As shown in Figure 3E, responses of Ca_{2.2}−/− mice are generally lower than those of Ca_{2.2}+/+ and +/+ mice. At the sound intensities of 115 and 120 dB, the responses are significantly lower in Ca_{2.2}−/− mice. This phenotype also seems to be compatible with the above-mentioned reduced anxiety in Ca_{2.2}−/− mice.

**Abnormal pain responses in Ca_{2.2} mutant mice**

As mentioned above, Ca_{2.2} mutant mice showed no signs of motor dysfunction. This suggests that it is possible to study pain responses of the mutant mice by assessing their behaviors towards painful stimuli. Thus we used the mutant mice to examine the contribution of the N-type VDCC to pain transmission *in vivo*.

First, responses to acute mechanical and thermal stimuli were examined. The threshold for mechanical stimuli evaluated with von Frey filaments (Chaplan *et al.*, 1994a) was almost the same among Ca_{2.2}+/+, +/− and −/− mice (Figure 4A). We also measured the threshold for noxious mechanical stimuli by the tail pressure test. Again, no significant differences were observed among the three
genotypes (Figure 4B). Next, we examined the responses to noxious thermal stimuli by paw flick, tail flick and hot plate tests. The paw flick and tail flick tests were used to examine the spinal reflexes at the lumbar and sacral levels, respectively, and the hot plate test examined a supraspinal involvement in nociception (Chapman et al., 1985). Although Ca2.2−/− mice showed no significant differences in the response for the paw flick and hot plate tests, they showed somewhat prolonged latency in the tail flick test compared with Ca2.2+/+ and +/− mice (Figure 4C–E).

We then analyzed the responses to chemical stimuli by the formalin test and acetic acid writhing test. Injection of formalin into a mouse hindpaw elicits a biphasic pain response. In phase 1, formalin directly stimulates nociceptors to induce the pain response, and in phase 2 subsequently induced inflammation elicits the pain response (Tjølsen and Hole, 1997). The phase 1 responses of Ca2.2−/− mice, as measured by the licking/biting time, were essentially the same as those of Ca2.2+/+ and +/− mice (Figure 5A). Furthermore, the phase 2 responses of the Ca2.2−/− mice did not differ significantly from those of Ca2.2+/+ and +/− mice, although Ca2.2−/− mice tended to respond less markedly. Interestingly, however, a clear-cut statistically significant difference was observed when the time course of the response was analyzed in more detail, i.e. Ca2.2−/− mice showed significantly reduced responses in the early half of phase 2 (Figure 5B).

To determine whether the magnitude of the inflammation itself decreased, we measured the paw volume before and after administration of formalin. The magnitude of inflammation 1 h after the formalin injection, as expressed by percentage inflammation [(Vpost − Vpre)/Vpre × 100], where Vpre and Vpost are the paw volumes measured before and after formalin injection, respectively, was not significantly different among the three genotypes (55.6 ± 7.1% for +/+; n = 4; 66.0 ± 6.0% for +/−; n = 4; 55.8 ± 11.2% for −/−; n = 4). Therefore, the reduced pain responses in Ca2.2−/− mice do not seem to be attributable to the reduced inflammation.

We then performed the acetic acid writhing test. Intraperitoneal injection of acetic acid induces a typical behavior (writhing) in mice, which is used for quantifying
visceral pain with inflammation (Tjølsen and Hole, 1997). The number of writhes of the Ca$_{2.2}$−/− mice was not significantly different from those of Ca$_{2.2}$+/+ and +/- mice (Figure 5C). Recently we have established a behavioral paradigm to assess an extremely long-lasting descending antinoceptive mechanism (Kurihara et al., 2000). We have used this paradigm to find that Ca$_{2.3}$ (α1E) channel-null mutant mice have a deficit in the antinoceptive pathway (Saegusa et al., 2000). We also applied this test to the Ca$_{2.2}$−/− mice. First, mice received an i.p. injection of acetic acid to activate the antinoceptive pathway. Three weeks later, they were subjected to the formalin test. As shown in Figure 5D, phase 1 responses were almost the same as control responses in all the genotypes. In addition, in the wild-type, phase 2 responses in the sensitized mice became weaker compared with those of naive mice when tested with formalin [a behavioral manifestation of the activated antinoceptive pathway (Kurihara et al., 2000)]. However, phase 2 responses in sensitized Ca$_{2.2}$−/− mice increased compared with those of naive Ca$_{2.2}$−/− mice (Figure 5D). Although data scattered substantially, responses in the early half of phase 2 still tended to be suppressed, whereas responses in the later half of phase 2 dramatically increased in the Ca$_{2.2}$−/− mice (data not shown).

We previously reported that the Ca$_{2.3}$ channel might be involved in the descending antinoceptive mechanism which is thought to contain a serotonergic system (Saegusa et al., 2000). Therefore we also examined the expression of Cacna1b in the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM), both of which are suggested to be involved in the antinoceptive mechanism. Expression of Cacna1b was detected in a wider area of PAG than that of Cacna1e and was detected in the RVM including nucleus raphe magnus, where serotonergic neurons that might be involved in the pain modulatory system originate and where Cacna1e expression is hardly observed (not shown).

Next we studied the responses related to neuropathic pain in the Ca$_{2.2}$−/− mice. The spinal nerve ligation model has been used commonly as a model for neuropathic pain (Kim and Chung, 1992; Tjølsen and Hole, 1997). We applied this model to the Ca$_{2.2}$ mutant mice and quantified the extent of mechanical allodynia and thermal hyperalgesia accompanied by the neuropathic pain (Devor and Seltzer, 1999; Woolf and Mannion, 1999). The threshold for mechanical stimuli was determined by the von Frey test to assess mechanical allodynia, and the responses to heat stimuli were examined by the paw lick test to assess thermal hyperalgesia. As shown in Figure 6A and B, both Ca$_{2.2}$+/+ and +/- mice developed robust mechanical allodynia and thermal hyperalgesia. On the other hand, Ca$_{2.2}$−/− mice developed markedly reduced signs of neuropathic pain.

The N-type VDCC is known to be involved in the functions of the sympathetic nervous system, impairment of which might complicate the interpretation of the above-mentioned pain-related behaviors of the mutant mice. For example, impaired sympathetic function is thought to result in changes in body temperature, which might in turn affect paw withdrawal latency in the paw lick test. Therefore, we measured the peripheral body temperature of the mutant mice and compared it with that of wild-type controls. However, the result shows no significant differences in the peripheral body temperature (29.0 ± 0.64°C for +/-, n = 8; 28.5 ± 0.37°C for −/−, n = 8; 28.2 ± 0.48°C for −/−, n = 5). We also examined the resting heart rate and blood pressure of the Ca$_{2.2}$ mutant mice as indices for sympathetic nervous system functions, but again the data suggest no significant differences (heart rate: 564.3 ± 21.9 b.p.m. for +/-, n = 11; 617.7 ± 19.8 b.p.m. for −/−, n = 14; 547.0 ± 25.8 b.p.m. for −/−, n = 4; blood pressure: 107.3 ± 3.4/59.8 ± 2.6 mmHg for +/-, n = 11; 113.3 ± 2.6/64.5 ± 2.1 mmHg for −/−, n = 14; 111.6 ± 3.5/59.5 ± 2.8 mmHg for −/−, n = 4).

**Discussion**

In this study, we generated mice lacking the α1.2.2 subunit of the N-type VDCC. Ca$_{2.2}$−/− mice showed a partial lethality, i.e. ~70% of the homozygous mutant mice survived to adulthood. This lethality is lower than that of mice lacking Ca$_{2.1}$ (or homozygous for *leaper*, a hypomorphic allele for the *Cacna1a* gene encoding Ca$_{2.1}$), which show almost fully penetrant lethality before weaning (Fletcher et al., 1996; Jun et al., 1999). The lower degree of lethality is also predicted by the results of studies with toxins that block VDCCs. Low doses of ω-agatoxins that block the Ca$_{2.1}$ channel are lethal to rodents, but higher doses of ω-conotoxins that block the Ca$_{2.2}$ channel are not (Chaplan et al., 1994b; Malmberg and Yaksh, 1994). However, the reason for the reduced viability in Ca$_{2.2}$−/− mice is not clear and awaits further studies.

Ca$_{2.2}$−/− mice displayed reduced anxiety-like behaviors, as assessed by the elevated plus-maze and open-field
tests, widely used tests to examine rodents’ anxiety (Tarantino and Bucan, 2000). In addition, the results of
the startle response tests are also consistent with the notion that the Ca,2.2−/− mice have reduced anxiety. Although
there remains a possibility that the reduced startle responses are due to an attenuated spinal reflex, this
seems unlikely because locomotor activities were generally normal. The reduced level of anxiety in Ca,2.2−/−
mice is in contrast to the situation in the Ca,2.3-null mice, which show rather enhanced anxiety-like behaviors
(Saegusa et al., 2000). This suggests that the contribution of these channels to an animal’s emotional state is
different, although their expression domains in the brain overlap substantially (Williams et al., 1994; Ludwig et al.,
1997). It may be interesting to dissect the molecular mechanisms that produced this difference in the emotional
state in a future project.

Ca,2.2−/− mice showed almost normal responses to acute nociceptive stimuli compared with Ca,2.2+/+ mice,
except for the responses in the tail flick test. It seems rather strange that Ca,2.2−/− mice showed different responses in
the two similar assays, paw flick and tail flick tests. The difference may be explained by the different sensitivities of
the assays or by the possibility that different neural mechanisms underlie both assays. However, it is more
conspicuous that Ca,2.2−/− mice displayed some abnormal responses in the tests to quantify inflammatory pain. It
is of interest that Ca,2.2−/− mice showed a reduced level of responses only in the early half of phase 2 of the
formalin test (Figure 5B). This early half of phase 2 seems to correspond to phase 2A reported by Yaksh and
colleagues (Malberg and Yaksh, 1992; Dirig et al., 1997). They proposed that phase 2 could be separated
further into two qualitatively different subphases: phase 2A, the first half of phase 2 in which pain responses are
sensitive to anti-inflammatory drugs such as cyclooxygenase inhibitors; and phase 2B, the latter half of phase 2
in which pain responses are resistant to these drugs (Malberg and Yaksh, 1992; Dirig et al., 1997). Our result
further confirmed the presence of two distinguishable subphases in phase 2 and indicates that phase 2A is
completely dependent upon the N-type VDCC function. Previous studies using ω-conotoxins, however, showed
that both phase 2A and phase 2B were dependent upon N-type VDCC function (Malberg and Yaksh, 1994).
This apparent discrepancy may be attributable to some compensation mechanisms that occurred only in phase 2B
in the Ca,2.2−/− mice. Elucidation of the exact mechanism by which the N-type channel controls the phase 2A
responses awaits further studies, but one possibility is that the N-type VDCC controls release of neurotransmitters
from the primary afferent fibers, which is induced by prostanooids generated by cyclooxygenases (White, 1996;
Zimmer et al., 1998).

The Ca,2.2−/− mice showed the increased level of phase 2 responses in the formalin test after sensitization with i.p.
injection of acetic acid (Figure 5D), and in this case the phase 2A responses were also suppressed (data not shown).
We previously reported that Ca,2.3-null mice also showed reduced phase 2 responses in the normal formalin test
and enhanced phase 2 responses after sensitization with a visceral noxious conditioning stimulus. In this respect,
the effects of elimination of either the Ca,2.2 or Ca,2.3 channel seem to be similar. However, there was no differential
effect on phase 2A and 2B in the case of Ca,2.3-null mice, i.e. responses in both subphases were affected equally (unpublished observation). In this
context, it is interesting that Cacna1b and Cacna1e (encoding the Ca,2.3 channel) show different expression
patterns in the RVM, where pain modulation mechanisms (both inhibitory and facilitatory) are thought to occur
(Mason, 1999). Thus, both N- and R-type (coded by Ca,2.3) VDCCs are involved in the inflammatory pain
transmission and descending antinociceptive pathway, but the physiological roles of each channel seem to be quite
different. Further studies are necessary to relate the expression of these channels and the abnormal phenotypes
of the respective mutants.

Finally, and most importantly from a clinical point of view, the Ca,2.2−/− mice showed a greatly reduced level
of neuropathic pain symptoms. This unequivocally demonstrates that the N-type VDCC is essential for the
mechanism to develop neuropathic pain, suggesting that blockers of this channel are useful for preventing
neuropathic pain. However, it has been demonstrated that clinical application of ω-conopeptide has a limitation
due to its side effects (Penn and Paice, 2000). Intrathecal injection of ω-conotoxin GVIA, the dose of which is
enough to elicit motor deficits in Ca,2.2+/+ mice, did not induce any overtly abnormal behaviors in Ca,2.2−/−
mice (our preliminary observation), suggesting that the side effects mentioned above result from the blockade of the
N-type VDCC. Thus the fact that the Ca,2.2−/− mice did not show any motor deficits might suggest some compen-
sation mechanisms in Ca,2.2−/− mice. Therefore, it may be important to explore the possible compensation
mechanism in future studies. Otherwise, it would be difficult to use ω-conopeptides as antinociceptives
avoiding their side effects.

Materials and methods

Gene targeting
Genomic clones containing the Cacna1b gene were screened from the 129/Sv mouse genomic library (Stratagene) with a 222 bp HindIII–HincII
fragment (5’ linker–nucleotide 213) from pKCRB3 (Fujita et al., 1993) as a probe. Lambda phage clones were isolated and the inserts were
subcloned into pBlueScript II KS(+) (Stratagene).

Targeting vector BIIIZeneI was constructed using a 2.2 kb BglII–Nol fragment and a 6 kb XbaI–EcoRI fragment as 5’ and 3’-homologous
regions, respectively (Figure 1A). A 1.6 kb region from the Nol site in exon 1 to an XbaI site in intron 1 was deleted, and nlacZ (a gene for
Escherichia coli β-galactosidase with a nuclear localization signal at its N-terminus) was inserted in-frame. A positive selection marker
(neomycin resistance gene driven by the phosphoglycerate kinase promoter) was also inserted in the direction opposite to that of nlacZ
transcription. The diphtheria toxin A fragment gene driven by the MCI
promoter was used as a negative selection marker (Yagi et al., 1990).

BIIIZeneI was linearized with Apol and electroporated into J1 ES cells (derived from the 129/Sv strain) (Li et al., 1992). Homologous
recombinant ES cells were screened by Southern blot analysis. Mutant mice were generated by standard techniques (Papaioannou and Johnson,
1993). An F1 heterozygous mutant with a hybrid background of C57Bl/6 (B6) and 129/Sv was backcrossed once against B6 and the resulting
heterozygous offspring were intercrossed to obtain homozygous mutant mice.

Southern and northern blot analyses
Procedures are essentially the same as described (Saegusa et al., 2000). Probes were labeled with digoxigenin (DIG) using the DIG-High prime
kit (Roche Molecular Biochemicals) and detected with alkaline
phosphatase (AP)-conjugated anti-DIG antibody. CSPD® or CDP-Star™ (Roche Molecular Biochemicals) was used as a substrate for AP.

**RT–PCR**

RT–PCR was essentially the same as reported (Saegusa et al., 2000). Primers used were mA1B-F1 (5’-ATGGTCCGCTTCCGGGAC-3’), corresponding to an upper fragment from the nla2 insertion site in exon 1 of Caunaib and mA1B-R1 (5’-AATGCACTTTGCGATGATG-3’, possibly located in exon 2). This primer pair yielded a 330 bp DNA fragment from normal Caunaib cDNA.

**Immunoblotting**

The procedure is essentially the same as that reported previously (Saegusa et al., 2000) except that crude membrane fractions were prepared from hippocampi, because of the relatively abundant expression of the Ca,A,2 channel in the hippocampus. The blot was probed with a rabbit polyclonal anti-α1,2.2 (α4) or anti-α1,2.3 (α5) antibody (both from Alomone Laboratories, Jerusalem, Israel).

**Electrophysiological recording**

DRG neurons from adult mice were acutely dissociated by a slight modification of the method of Scroggs and Fox (1992). Briefly, DRGs from the lower thoracic (T8) to lumbar level (L6) were quickly removed, treated with 2 mg/ml collagenase (type I, Sigma) and 2.5 mg/ml dispase I (Roche Molecular Biochemicals) in Tyrode solution (150 mM NaCl, 4 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES and 10 mM glucose, adjusted to pH 7.4 with NaOH at 37°C for 60 min, and then treated with dispase I alone at room temperature (22–25°C) for 60 min. DRG neurons were dissociated into single cells by trituration, plated on glass coverslips coated with poly-L-lysine (Sigma) and the coverslips were placed in a recording chamber on a microscope stage with superfusion (1.5 ml/min) with Tyrode solution.

Round-shaped DRG neurons were voltage-clamped by the conventional whole-cell patch–clamp techniques using an EPC-8 amplifier (HEKA, Germany) at room temperature (23–26°C). Pulse + Pulse Fit 8.11 software (HEKA) was used for data acquisition and analysis. In this study, we used relatively small DRG neurons (17–22 μm in diameter). These neurons would represent Aβ- and C-type DRG neurons, which are considered to transmit pain and thermal information under normal conditions (Raja et al., 1999). Patch pipettes were pulled from thin-walled, fiber-filled borosilicate capillaries using a micropipett puller (Sutter Instrument, USA) and fire polished. Pipette resistance ranged from 4 to 8 MΩ when filled with the pipet solution described below. Gigahm seal and entry into whole-cell mode were obtained in Tyrode solution. Series resistance was electronically compensated by 70–90%, and both the leakage and the remaining capacitance were corrected by the –P/4 method.

To isolate Ba2+ currents, the following solutions were employed: the pipet solution, 105 mM Cs-methanesulfonate, 4.5 mM MgCl2, 10 mM EGTA, 10 mM HEPES–CsOH, 4 mM Na2ATP, 1 mM NaGTP and 15 mM creatine phosphate, adjusted to pH 7.3 with CsOH; the external solution, 160 mM tetraethylammonium chloride, 2 mM BaCl2, 10 mM HEPES–CsOH, 10 mM glucose, 0.001 mM tetrodotoxin, adjusted to pH 7.4 with CsOH (310 mOsm). Media were filtered at 3–5 kHz (four-pole Bessel filter) and sampled at 5 kHz. In the experiments with α-conotoxin GVIA and α-agatoxin IV A (Peptide Institute, Inc., Osaka, Japan), the external solution was supplemented with 0.1 μg/ml cytochrome c. The blocking effects of these toxins on Ba2+ current amplitude were estimated from the plots of peak current versus time, with run-down taken into account as described previously (Scroggs and Fox, 1991). All data are presented as mean ± SEM, and statistical significance was assessed by Mann–Whitney test.

**Behavioral studies**

All the experiments were conducted under the ethical guidelines for the study of experimental pain in conscious animals (International Association for the Study of Pain, 1995), and the protocol of the pain behavioral studies described here has been approved by the Animal Care Committee of Tokyo Medical and Dental University. All the experiments were performed in a blind manner. The data were expressed as mean ± SEM and analyzed by Tukey test for multiple comparisons or by Student’s t-test for comparison between groups. Open-field, elevated plus-maze, startle response, von Frey, paw flick, tail flick, hot plate, formalin and acetic acid writhing tests were carried out according to the methods described previously (Saegusa et al., 2000).

**Tail pressure test.** The local pressure required to elicit tail withdrawal was quantified with an Ugo Basile Analgesymeter (Ugo Basile, Italy). The noceptive threshold was defined as the force in grams.

**Neuropathic pain model.** Spinal nerve ligation was carried out under sodium pentobarbital anesthesia as described previously (Kim and Chung, 1992). Briefly, a midline incision was made in the skin of the back at the L4–S2 levels and the right paraspinal muscles were separated from the spinous processes, facet joints and transverse processes at the L4–S1 levels. The L5-L6 transverse processes were removed, and the right L5 and L6 spinal nerves were ligated tightly with 8-0 silk thread.

**Acknowledgements**

We thank M.Kondo, M.Tamura, E.Tominaga, T.Muno, N.Yoneda, S.Inada, L.Gunsten, C.Le and staff at Animal Research Center of Tokyo Medical and Dental University for assistance, Professor T.Noda for kindly providing us with the cloning vectors for gene targeting and J1 ES cells, Drs M.Osana and Y.Sakata for technical advice, and Dr T.Murakoshi for critically reading the manuscript. This work was supported by grants from the Ministry of Health and Welfare, the Ministry of Education, Science, Sports and Culture, Japan, the Uehara Memorial Foundation and the Naito Memorial Foundation.

**References**


Li,E., Bestor,T.H. and Jaenisch,R. (1992) Targeted mutation of the DNA

2355


Received November 20, 2000; revised March 15, 2001; accepted March 19, 2001